Diabetes Connections | Type 1 Diabetes

Today on Diabetes Connections.. a bonus episode all about finding support and community online and in real life. Seems to be a theme lately and I could NOT be happier. Type One Together started with one college student, a few babysitting jobs, and a realization that there was a need. Type One Together has become something much bigger – they'll still help you find a sitter but they're also a hub for T1D info, support and gatherings. I'm talking to the founder, Raquel Baron, about how they got there, what kind of help they provide and what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Type One Together's events here - use promo code "connections" to save Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Senate Insulin Act moves forward, FDA approveds Awiqli for type 2 and and second oral GLP-1 pill, lots of updates on stem cell and gene therapy for type 1, updates from Beta Bionics, veterans group and Dexcom team up, and Omnipod features on Scrubs. Much more in the episode! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Stacey mentioned these two groups: Grownup T1Ds T1D to 100 Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

There's a reason we don't call it juvenile diabetes anymore. We all know you grow up and T1D doesn't go anywhere, and that you can be diagnosed at any age. But it often feels like adults are forgotten. I hope that's not the case here—but I hear it all the time in the broader community. Kelly Dawes is working to change that. She's started GrownUp T1Ds, a community built specifically for adults who've been living with type 1 for years and are finally finding connection, understanding, and support in a way they may never have had before. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Grownup T1Ds here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com transcript with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it. https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice. The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests XX Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments. https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly

We all know how important mental health is but unless you are VERY lucky, you're on your own. There are the rare programs out there for pediatric endocrinology and we've got one of the best Dr. Taylor Stephens is a pediatric psychologist with the Cleveland Clinic who specializes in pediatric endocrinology conditions. She's here to share what we can all do, right after diagnosis, and years later to support our kids and ourselves, if you're a caregiver or an adult living with type 1 This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about the Mental Health + Diabetes Conference here. Use promo code "dmhconnections" to save 15% off your ticket Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

Bonus episode! I had the opportunity to talk to the folks at Dexcom about their presentations at ATTD and I wanted to bring you the interview sooner rather than later. ATTD is the Advanced Technology and Treatments for Diabetes conference, this year it took place in Barcelona. If you're new around here, there are a few big diabetes conferences where studies are presented and news is made. ATTD in spring, ADA and ADCES in summer and a few more scattered here and there. We'll be sharing more from ATTD in upcoming interviews with other tech companies. But today I'm talking to Jessica Castle, VP of Medical Affairs at Dexcom – she's also an adult endocrinologist with a lot of clinical trial experience. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, "Lyla's Law" Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdown Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com transcript with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. I am definitely feeling better – that lingering cold is gone – but whew still recovering from non stop travel for the past five weeks. I have a great strech of time her at home, then going to Vegas for Brekathorugh T1D at the end of the month and we have two club 1921 events in April – Atlanta and Philly. Before we jump into the news – I need your community commercials! These have been a lot of fun, I announced them late last year – your voice on the show. All the instructions it's very easy in the show notes. Okay.. our top story this week: XX A biotech company developing stem-cell treatments for type 1 diabetes has announced a new research partnership aimed at improving the survival of transplanted insulin-producing cells. NewcelX, a clinical-stage company based in Switzerland, said it will work with Eledon Pharmaceuticals to study a combination approach. The goal is to help transplanted cells survive longer in the body by reducing the immune response that often leads to transplant rejection. If successful, the strategy could support longer-lasting islet cell replacement and move the therapy closer to becoming a functional treatment for people with type 1 diabetes. However, the companies have not yet released any safety or effectiveness data on the combination treatment, and financial details of the partnership were not disclosed. The research agreement is focused on exploring whether combining stem-cell-derived islets with targeted immune therapy can lead to longer-lasting cell transplants and improved outcomes for people with type 1 diabetes. https://www.stocktitan.net/news/ELDN/newcel-x-announces-strategic-collaboration-with-eledon-d10l1vqdofls.html XX Debate this week in the UK on whether testing for type 1 diabetes should become mandatory when children present with symptoms. The Westminster Hall debate, scheduled for 9 March, will consider calls for routine testing of babies, toddlers and young children who show signs associated with the condition. It follows a petition backing the move, dubbed 'Lyla's Law', which passed 121,000 signatures in December 2025. The campaign was launched by John Story after his two-year-old daughter, Lyla, died from diabetic ketoacidosis (DKA) on 3 May 2025, 16 hours after being diagnosed with tonsillitis. https://www.nursinginpractice.com/clinical/diabetes-and-endocrinology/diabetes-community-urged-to-call-on-mps-to-attend-lylas-law-debate/ XX A new study suggests that people with gestational diabetes who adjust their own insulin doses may reach healthy blood sugar levels faster than those whose doses are adjusted by clinicians. Half of the participants were assigned to adjust their own insulin doses using a simple rule: increase the dose by two units if fasting blood glucose was above 95 mg/dL, decrease it by two units if it dropped below 70 mg/dL, and keep the same dose if levels fell in between. The other half had their insulin adjusted by clinicians through weekly reviews. By the end of pregnancy, both groups had similar average fasting glucose levels before delivery: about 89 mg/dL in the patient-led group and 90 mg/dL in the clinician-led group. However, those adjusting their own insulin reached their blood sugar targets more quickly, averaging 1.8 weeks compared with 2.5 weeks for those managed by clinicians. The study also found lower risks of certain complications among the patient-led group. https://www.medscape.com/viewarticle/self-insulin-dosing-leads-control-gestational-diabetes-2026a1000729 XX A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries. Semaglutide, the active molecu

Why don't we talk about our skin more?! When you or your child is diagnosed with diabetes, you quickly realize the skin is in for a rough time. Endless pokes from needles, infusion sets, CGM wires. You make it work, but what if there was a better way? I'm talking Marie Schiller and Kent Manson – they've teamed up to help with a solution now and one they're working on for the future. The available now treatment is Site Hero – a recovery patch to help sites heal.. and – for the future - a way to scan an area and help identify better injection or infusion sites at home. This is a great and practical conversation. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Site Hero and Healthy Sites here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/ Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells. After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed. Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost

Tidepool was founded in 2013, part of the incredible era of DIY diabetes progress, and has since helped change how hundreds of thousands of people with diabetes see and use their data. I'm talking to CEO Brandon Artibter about how open-source innovation became FDA-cleared technology, and what's next.. including a new partnership with Oura Ring to study sleep, activity, and menstrual cycles, and continued work with Tidepool Loop. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episodes with Tidepool, including the announcment of bringing Loop to the FDA back in 2018! https://diabetes-connections.com/?s=tidepool Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: T1D in the Olympics & Superbowl, Trump RX goes live, Ozempic pill available soon, tech updates from Medtronic, Beta Bionics, Eversense 365 and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: We are just over one week from our first Moms' Night Out event of the year. While the plans are all set – the speakers, the vendors, the raffles and the fun is ready to go, it's always amazing how many people hear of these event last minute. That's fine, they're welcome! But if you're thinking of attending a future event – registration is open for We're going to Nashville next March 6-7 and Detroit in September – no need to wait. And we've got Club 1921 events for health care professionals and patient leaders in 6 cities this year! All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX Gotta be a quick shout out to some incredible T1D athletes – we had TWO in the super bowl this past weekend – Chad Muma of the New England Patriots and Logan Brown of the Seattle Seahawks AND there are at least two athletes with type 1 competing at the Winter Olympics. Hannah Schmidt competes in ski cross for Canada – she was diagnosed with Type 1 diabetes at age 12 years old. Anna FarnSchadt Fernstäd a Czech skeleton racer diagnosed in 2022 after she'd already been to several Olympics. We wish them all the best! https://english.radio.cz/skeleton-racer-anna-fernstadtova-overcoming-adversity-headfirst-down-ice-8876699 XX The government website TrumpRx.gov is live.. the website does not sell prescription drugs. Instead, it allows people to look up their drugs and then navigate to buy them elsewhere, either from a major drug company or a pharmacy. The 43 drugs listed on the site have prices ranging from $3 to over $5,500. TrumpRx does include warnings that the site may not be the best option to save money on prescriptions. Each product page advises: "If you have insurance, check your co-pay first — it may be even lower." For now, the website says its prices are for people paying with their own money, rather than going through insurance. The only insulin listed right now is Lilly's insulin lispro – and it's the same price as you'd find through Illy's insulin value program. I looked up diabetes meds.. For example, if you have an insurance co-pay of $25 a month for Farxiga, a drug often used for diabetes, you would be paying $182 on TrumpRx. As you can imagine, though ,this is complicated and as with most of our healthcare system, it may be good in some cases and not much help in other. I'd suggest calling your local pharmacist or checking with your human resource dept. https://www.nytimes.com/2026/02/06/health/trumprx-prescription-drug-prices-consumers.html XX Novo Nordisk will launch some doses of its oral semaglutide for diabetes under the brand name Ozempic pill in the second quarter of this year. The company said the U.S. Food and Drug Administration has approved Ozempic tablets in three different doses. Novo says The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes Semaglutide tablets have been available under the brand name Rybelsus Ruh BELL sis for diabetes since 2019 but with different dosing. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-launch-ozempic-pill-diabetes-second-quarter-this-year-2026-02-04/ XX https://www.contemporarypediatrics.com/view/early-screening-for-type-1-diabetes-found-effective-in-children XX Possible new way to identify and track the progress of type 1 diabetes before clinical onset. A recent study published in Science Advances described the application of subcutaneous microporo

Two years ago the FDA pulled down just about every insulin calculator app. A lot of them just disappeared, rather than seek official approval, but one of them – created by a teenager with type 1 – is back. I'm talking with Drew and Mike Mendelow about the relaunch of T1D1, a free and ad-free insulin-dose calculator app. They share what it was like to navigate the FDA process, how they go international help, and what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: UK looks at starting universal T1D screening, Dexcom's CEO mentions a new product, bariatric sugery vs GLP medications, FDA approves update to prescribing info for inhaled insulin, miscroplastic and diabetes link studied, and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcription with links: (Stacey Track) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. We are less than one month from our first MNO of 2026. Please join us in Silver Spring MD Feb 20 and 21. It's going to be amazing. We're going to Nashville next March 6-7 and we're going to have a great event a Club 1921 we just added on Thursday March 5th for health care providers and patient leaders. All the info is over at diabetes-connetionss.com events/ Okay.. our top story this week: XX All UK children could be offered screening for type 1 diabetes using a simple finger-prick blood test, say researchers who have been running a large study. This is the ELSA study - Early Surveillance for Autoimmune diabetes, a first of its kind UK study. They tested blood samples from 17,931 children aged 3-13 for autoantibodies, markers of type 1 diabetes that can appear years before symptoms. Families of children found to have early-stage type 1 diabetes received tailored education and ongoing support to prepare for the eventual onset of type 1 diabetes symptoms and to ensure insulin therapy can begin promptly when needed, reducing the chances of needing emergency treatment. Those with one autoantibody also received ongoing support and monitoring. Some families were also offered teplizumab, the first ever immunotherapy for type 1 diabetes, which can delay the need for insulin by around three years in people with early-stage type 1 diabetes. The second phase has launched and will expand screening to all children in the UK aged 2-17 years, with a focus on younger children (2-3 years) and older teenagers (14-17 years). The research team aims to recruit 30,000 additional children across these new age groups. ELSA 2 will assess how screening can be scaled across the NHS and evaluate its cost-effectiveness. https://www.birmingham.ac.uk/news/2026/childhood-type-1-diabetes-screening-is-effective-and-could-prevent-thousands-of-emergency-diagnoses XX At the J.P. Morgan Healthcare Conference Dexcom CEO Jake Leach says they're going to launch a new product outside the US. I'll link up that interview, The full quote: "When you look at the outside the U.S., there are a lot of structures that are tiered. Patients have access to different types of products, so we've got a new one that we want to introduce that will add flexibility there. It's based on the G7 platform, just like Dexcom ONE+, but it has a unique experience that's tailored for a subset of users that, today, don't have access to Dexcom." Your guess is as good as mine, but sounds more like a pricing or ordering issue than a new bit of hardware or software. Dexcom will also bring Stelo to some international markets this year. And plans a new mobile app experience for the wearable biosensor meant for people who don't dose insulin. Leach also says G8 will be much smaller and with more capability. but is a few years away. https://www.drugdeliverybusiness.com/dexcom-ceo-jake-leach-2026-roadmap-jpm/ XX A new international consensus statement provides guidance for the use of diabetes technology during pregnancy for women with type 1 diabetes (T1D), type 2 diabetes (T2D), or gestational diabetes (GD). Organized by the diaTribe Foundation, the document was based on evidence where available, as well as opinion from an international group of experts in endocrinology, diabetes technology, and obstetrics & gynecology, among others. This is the first set of recommendations specifically addressing the use of diabetes technology in pregnancy – and we'll link it up. https://www.medscape.com/viewarticle/new-consensus-statement-addresses-diabetes-tech-pregnancy-2026a100020d XX Bariatric surgery beats GLP-1s for type 2 diabetes across income levels. This study was published this month, looking at nearly 300 patients are 4 medical centers. Success here is measured by lower blood glucose levels, higher weight loss (28% vs. 10%), less use of

Imagine getting your kids screened for T1D and agreeing to do it yourself, just to set a good example, and then your test is the one that comes back with type 1! That's exactly what happened to Chris Dunn. She was positive for all of the autoantibodies and has since been treated with Tzield, the medication shown to delay the onset. We're talking to her about all of that, what the treatment is actually like, how she's doing since and what her family thinks of the whole thing. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us for an All Things Camp webinar TONIGHT 1/20 8pm ET Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

It's In the News... the top diabetes stories and headlines happening now! Top stories this week include: new islet encapsulation trial, FDA agrees to review Tzield for babies and approves the MiniMed Go, Civica releases it's version of Lantus, Eversense launches with a pump partner, scholarship for college students with diabetes and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life All about Dexcom Screen it Like You Mean It All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcript: Welcome! This is an In the News episode.. we're doing things a little differently this year, but we are still bringing you the top diabetes stories and headlines happening now. We are rotating these shorter episodes with our longer, interview episodes.. but all on Tuesdays now. And that's why you'll hear ads on the in the news episodes. My usual disclaimer – we believe in the products advertised here but no one tells me what stories to run or what to say – the commercials are separate from the news. I know most podcasters don't do disclaimers anymore, but I come from traditional broadcasting and it's still important to me. Okay.. our top story this week: XX Positive results for a phase 1 clinical trial of encapsulated islets in people with type 1 from Encellin. This first-in-human trial is assessing (1) safety and adverse events, (2) cell survival within the device, and (3) fibrosis, or scarring, around the implants. As planned, ENCRT devices were removed from the initial five participants after 4 months of implantation. Analysis of the removed devices show: minimal to no fibrosis (formation of scar tissue around the device); robust formation of blood vessels around the device; viable islets inside the device. These results indicate that the device has the potential to host islet cells while maintaining sufficient oxygen and nutrient flow for the cells to work effectively. Breakthrough T1D's Role: Encellin's technology was originally developed within the Lab of Dr. Tejal Desai (University of California San Francisco) with funding from Breakthrough T1D, which was crucial in the formation of Encellin as a company and attracting subsequent venture capital. https://breakthrought1d.ca/cell-therapy-trial-encellins-device-delivers-promising-early-results/ XX The US Food and Drug Administration has accepted Tzield for priority review to expand the current age indication from eight years and above, to as young as one year old and above to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. The target action date for the FDA decision is April 29, 2026. "This priority review emphasizes the urgent need for innovative therapies like Tzield which has the potential to prevent the natural progression of T1D by delaying the loss of endogenous insulin production. This might be particularly significant in this young population, as it is well documented that the autoimmune attack that drives this disease in many cases, begins, early in life," said Christopher Corsico, Global Head of Development at Sanofi. "If approved, Tzield could represent an important advance for delaying the onset of stage 3 type 1 diabetes in early childhood, which would benefit patients and caregivers alike." Interim data for the PETITE-T1D phase 4 study was presented at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes and simultaneously published in Diabetologia. Priority review is given to regulatory applications seeking approval for therapies that have the potential to provide significant improvements in the treatment, diagnosis, or prevention of serious conditions. The safety and efficacy of Tzield in the PETITE-T1D population has not been approved by any regulatory authority. https://www.globenewswire.com/news-release/2026/01/05/3212420/0/en/Press-Release-Sanofi-s-Tzield-accepted-for-priority-review-in-the-US-for-young-children-with-stage-2-type-1-diabetes.html XX Sanofi said the U.S. Food and Drug Administration accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old. The French pharmaceutical company said Monday that the FDA's review could amend the lower end of the range for the drug, which is currently approved for children as young as eight years old. Tziel

One of the sure-thing top stories of 2026 will be GLP1s, but will we see more studies and even approval for treating type 1 with these medications? We're talking about Ozempic, Mounjaro and the next versions like Retatrutide - that are just around the corner. I'm talking to Dr. Cecelia Lo Wong, a diabetologist at the University of Colorado whose been on the front lines of this conversation for years, including serving on FDA advisory committees. This is a wide ranging interview - we also talk about the growing needs of older adults with type 1 diabetes, how kidney and cardiovascular risk guidelines are evolving, and why managing diabetes in the hospital can still be such a challenge. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. This week's Community Commercial is from Lisa Katzenberger, the author of "It Belongs to the World," a children's book version of the story of Frederick Banting and the discovery of insulin. Learn more about this book here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

It's In the News.. a look at the top headlines and stories in the diabetes community. This week we're also making predictions for diabetes news in 2026! This week's top stories: statins and type 2, big results from Lilly's newest weight loss drug, MiniMed IPO, Tandem app update, and more! Predicitons include thouhts around: continuous ketone monitoring, noninvasive gucose moniotring, inhalable insulin for kids, GLP1 backlash, A1 slop in diabetes mom groups and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

This week on Diabetes Connections, a conversation about what really matters in diabetes. We're talking about the top stories of 2025, the hype that didn't happen, some trends for 2026, what community can accomplish, and what LeBron James has to do with all of this. We also get personal – because I'm being interviewed by the wonderful Neil Greathouse, host of Your Best T1D life, and so much more. This episode contains a replay of Your Best T1D Year. Check out Neil's great podcast! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

Making the case for a better at home A1C test. Orange Biomed is developing a compact, one-drop, at-home A1C testing device they say could make frequent A1C checks easier and more accessible than ever. They're passionate about closing the gap for people who struggle to get to clinics regularly… and the research they share is compelling: four A1C tests a year can lead to a nearly 4% reduction in A1C levels. We'll talk about why more frequent A1C monitoring matters—even in the era of continuous glucose monitoring—how their new device works, and what early clinical trial results look like. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Orange BioMed here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcript: Stacey Simms 00:05 Today on diabetes connections, making the case for a better at home A1C test. Orange biomed is developing a compact, one drop device that they say could make frequent A1C checks easier and more accessible. They're sharing research that four A1C tests a year can lead to a nearly 4% reduction in A1C levels, but they say a lot of people can't get to the clinic that much. We'll talk about why this matters, even in the era of CGM, how the device works and what the early clinical trial results look like. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your healthcare provider. Welcome to a bonus episode of diabetes connections. I hope your December is going well and that you know somehow you're able to take some time for yourself in the middle of all the holiday rushing around this time of year can be magical and stressful and exhausting and wonderful, and you know, all the things. And it's the same thing over here, super busy getting all this stuff done before the end of the year. Love it. But, you know, getting podcast episodes out, writing all the things we write and planning for next year, as they say, We're staying booked and busy. But quick behind the scenes here to better explain this episode, I taped this interview way back over the summer during the ADA Scientific Sessions conference. I had some technical problems. I actually thought I lost this interview. There were two interviews that seemed to have gone missing. We're going to air the other one very soon. But thankfully, I do have backups upon backups. So all the info that you're going to hear today is still relevant. This product, a small A1C test, is still in development. The only dated bit is about their follow up event that took place in August. Orange Biomed was launched in 2021 in South Korea, with its US headquarters in Providence, Rhode Island. Its founders are two Duke University alums, and they're my guests, CEO Yeaseul Park and Co-President Unghyeon Ko, We are also joined by Janice Dru-Bennett. She is a senior advisor at the company. Now, English is not the first language of two of these three speakers. This is a good time to remind you that most podcasting platforms have pretty good transcription services these days, especially Apple, I think they have a fantastic real time transcription service for podcasts that has been impressive to me in how they translate diabetes language. They're getting better at it. But I am also going to put a transcript of the interview in the show notes, which I don't normally do because the podcast services have gotten so good at it, but I think it could be helpful for at least a few of you out there. Okay, here is my conversation from the floor of ADA from the team at Orange biomed. Yeaseul Park, Janice Drew Bennett and Dr Ko, Welcome to diabetes connections. I can't say live from ADA, because we're taping this to air later, but you're all there. Thank you so much for joining Yeaseul Park 03:08 me. Yes, thank you. We're 03:10 excited to be here. Oh Stacey Simms 03:11 my goodness. Can I ask first, how is the trip? I mean, yes, let me ask you. You guys came a long way. Yeaseul Park 03:17 Yeah, it was 13 hours from Korea. But it's I'm so excited, because this event is really one of the times, and this is actually our third time attending ADA. Stacey Simms 03:31 That's great. And we have so many questions for you, but Janice, let me ask you, you're the

What if your glucose graph became a tangible piece of art? Something you could pring out and put on your water bottle or the back of your laptop. I've seen this in person and it makes a big impact on people. This week I'm talking to Krista Shenaman about making this type of art, her journey with type 2 – and it's been a journey, she took a "record breaking" 28 day walk after her diagnosis.. – why she thinks its helpful to look at data in a new way and more. Full disclosure: We recorded this interview way back in 2024! Technical issues and thought it was lost, but we found it. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

It's been a big month for announcements from Dexcom! What does that mean for you? From the commercial launch of the 15 day sensor and a smart basal feature to the announced phase out of the G6 and more, I'm talking with Jessica Castle, vice president of Global Medical Affairs at Dexcom. We're covering all of this news and she's answering your questions. More about the Dexcom 15 day here More about Dexcom G6 phase out here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

We're looking at some major policy issues happening in Washington, and what you can really do to effect change. George Huntley is the CEO of DPAC, the Diabetes Patient Advocacy Coalition. We've got a lot to cover: Medicare changes like competitive bidding that could dramatically limit access to CGMs and insulin pumps for seniors, the changing landscape around GLP 1 meds, and we talk about patient advocacy wins. I know some of you are cynical, but it can work. If you've ever thought your voice doesn't matter, this conversation may change your mind. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. Keywords Diabetes, D-PAC, Medicare, GLP-1 medications, patient advocacy, healthcare access, insulin pumps, CGMs, diabetes technology, legislative reform AI info below: Summary In this conversation, George Huntley, CEO of the Diabetes Patient Advocacy Coalition (D-PAC), discusses the critical role of advocacy in improving diabetes care and access to technology. He highlights the challenges faced by patients, particularly regarding Medicare coverage for insulin pumps and continuous glucose monitors (CGMs), and the implications of recent legislative changes. The discussion also covers the potential of GLP-1 medications in diabetes management and the importance of patient stories in advocacy efforts. Takeaways D-PAC focuses on affordable and equitable access to diabetes care. Advocacy is crucial for influencing healthcare policies. Competitive bidding for diabetes technology could limit access for seniors. Patient stories are essential in legislative advocacy. GLP-1 medications show promise in reshaping diabetes treatment. Economic factors play a significant role in healthcare access. The aging population of type 1 diabetes patients requires urgent attention. Collaboration among advocacy groups is vital for success. Healthcare costs are driven more by major medical expenses than by drug prices. Continued advocacy is necessary to protect patient access to care. Chapters 00:00 Introduction to Diabetes Advocacy 03:01 The Role of D-PAC in Diabetes Care 05:53 Challenges in Medicare Coverage for Diabetes Technology 09:11 The Impact of Competitive Bidding on Seniors 11:55 Advocacy Efforts and Legislative Challenges 14:57 The Future of GLP-1 Medications 17:56 Economic Implications of Diabetes Management 21:01 The Importance of Patient Advocacy 23:59 Healthcare Costs and Insurance Dynamics 26:56 The Need for Continued Advocacy 29:54 Conclusion and Call to Action

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big FDA recall around Freestyle Libre (see more below to find out if you're affected), Dexcom launches their 15.5 day sensor, Omnipod announces enhancements, Tandem tests a fully closed loop (with high fat, high carb meals) and lots more! Find out how to submit your Community Commercial Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. Our top story this week: XX Certain glucose monitors from Abbott Diabetes Care are providing users with incorrect glucose readings, an error that has been linked with the deaths of at least seven people and more than 700 serious injuries worldwide, according to an alert from the US Food and Drug Administration. Incorrect glucose readings can lead to improper treatment. Abbott warned that about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors are affected, but no other Libre products. Patients can visit FreeStyleCheck.com to see if their sensors are affected and to get a replacement for free. The FDA has also published specific information about the affected products in its alert. The agency considers this to be a "potentially high-risk issue" and will continue to update its website as information becomes available. "Patients should verify if their sensors are impacted and immediately discontinue use and dispose of the affected sensor(s)," the FDA said. https://www.cnn.com/2025/12/02/health/abbott-diabetes-glucose-monitors https://www.freestylecheck.com/us-en/home.html XX Omnipod 5 is getting some enhancements.. and Omnipod 6 is announced. The FDA cleared updates including a lower, 100 mg/dL target glucose option and what they call a more seamless automated experience. "This is the most significant algorithm advancement to our Omnipod 5 System since its launch in 2022," said Eric Benjamin, Insulet EVP and COO. Insulet said the new 100 mg/dL target glucose expands Omnipod 5's customization range. It now features six settings between 100 mg/dL and 150 mg/dL in 10 mg/dL increments. The company said this flexibility allows healthcare providers to tailor insulin delivery more precisely. It supports individuals seeking tighter glucose management or aiming to meet specific glucose goals. Omnipod 5's latest upgrades also help users stay in "Automated Mode" with fewer interruptions, even during prolonged high glucose events. Insulet plans to launch the updates to the algorithm in the first half of 2026. The company announced plans for an Omnipod 6 – without a lot of detail - at the company's Investor Day event in November. They also talked about a new, fully closed-loop pump for the type 2 diabetes population. https://www.drugdeliverybusiness.com/insulet-fda-clearance-omnipod-5-algorithm-enhancements/ XX Dexcom, the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System will launch in the United States on Dec. 1, making it the longest-lasting CGM system with 15.5 days of wear. Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers on Dec. 1 with full retail launch in the coming weeks. Dexcom G7 15 Day will also be covered for Medicare beneficiaries. Dexcom G7 15 Day's industry-leading wear-time will provide fewer sensor changes, less disruption and more time for people with diabetes to benefit from life-changing CGM technology. New with Dexcom G7 15 Day: Longest lasting CGM system with 15.5 days of wear. Best-in-class accuracy1 with an overall MARD of 8.0%. Easier glucose management with fewer monthly sensor changes and reduced monthly waste. This follows yesterday's announcement – the FDA has cleared Dexcom Smart Basal, the first and only CGM-integrated basal insulin dosing optimizer designed for adults 18 and older with Type 2 diabetes using long-acting insulin. Dexcom Smart Basal will use Dexcom G7 15 Day sensor data and logged doses to calculate personalized daily recommendations to guide users towards a more effective long-acting insulin dose, as directed by their healthcare provider.

We've got a research update on two of the topics you've told me you want to hear more about. First, research into Preventing type 1 – with a therapy that hasn't been in the headlines.. and second, inhaled insulin for kids. We're talking to Dr. Michael Haller, a peds endo who is at the forefront of these studies. We'll be talking about something called ATG – which looks really good in very low dose trials – and about the latest studies around inhaled insulin for kids – which is in front of the FDA right now. ATG studies and info here Afrezza for kids info here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

With lots of family time coming up this week for many of us, it's a great time to talk about screening for type 1. While this might seem to be a real downer of a Thanksgiving conversation, screening is now considered standard of care for people with a family history of T1D. My guests want to get the word out about that – and they've both walked the walk. Adam Schefter is ESPN Senior NFL Insider – his wife lives with type 1.. and Dr. Shara Bialo is a pediatric endo who lives with type 1. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More information about screening here Our previous episodes about TZIELD here Listen to our Thanksgiving themed episodes here Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

The Diabetes Sprots project says it's an organization built to inspire. What can we all learn about elite athletes with type 1 – the people running marathons and doing Iron Man competitions. And with the right support and education, how far can those athletes go? We're talking about the Olympics and more with DSP founder Casey Boren and volunteer Lauren Adams, both of whom live with type 1 (and both of whom had done a ten mile run before we started taping). Learn more about Diabetes Sports Project here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922. WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups. Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, sugge

We've got an update from Tandem Diabetes. We're talking about Libre 3 plus integration, Lyumjev approval, Mobi tubeless, extended wear infusion sets and a lot more with VP of Product Management Marisa Fienup. She's also answering your questions about tubing, alerts, and shares what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Information on RocketAP and other closed loop research Tandem earnings call info here Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

Taking a photo of your food and getting an accurate carb count seemed like a pipe dream just a few years ago, but this week's guest says it's here. Snaq wants to help you get nutritional info, and then see how that food actually affects blood glucose, thanks to integrations with CGMs, insulin pumps, and activity trackers. Snaq founder Aurelian Briner explains how his wife's type 1 diagnosis inspired the company, how it all works (and who owns the data), and what's next. Learn more about Snaq here Clinical Trial with Snaq here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

What can those of us who will never climb the highest mountains, or take on extreme outdoor challenges – learn from those who do? Patrick Mertes and Michael Shelver have hiked and biked – and fallen – on incredible expeditions, while living with type 1. They'll share what they've learned, how those lessons apply to everyday life with type 1, what their family's think and what's next. Plus, Patrick talks about why diabetes camps remain such a cornerstone of confidence and connection, and how parents can help their kids face challenges that truly build independence. This is the keynote address from Moms' Night Out Minneapolis. Make sure to join us in 2026 for this amazing event! More info: at the Moms' Night Out main page This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Project 50 in 50 Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

We all know how important exercise is for good health. And we all know how difficult exercise can be with type 1 diabetes. There's a new resource from some of the smartest people in our community. The folks at Diabetes Wise are adding exercise to their platform, which already has community and expert sourced information on devices. We're talking to the folks behind this move about what problems they want to solve, what's actually on the site and how to use it and how they manage their T1D while working out. You'll hear from Dr. Korey Hood and Dr. Dessi Zaharieva from DiabetesWise. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

n the News.. COVID-19 & T1D, Ozempic Pill Progress, Faster Insulin, "Beyond Misconceptions," and More It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new study looks at the link between COVID-19 and very young children, Lilly moves ahead with their Ozempic oral pill, ultra-rapid insulin clears another hurdle, Beyond Type 1 launches a new campaign and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX https://www.scientificamerican.com/article/advances-in-type-1-diabetes-science-and-tech/ This article is part of "Innovations In: Type 1 Diabetes," an editorially independent special report that was produced with financial support from Vertex. XX More evidence linking COVID 19 to type 1 diabetes.. but still exactly why is a mystery. During the COVID-19 pandemic, there was an unexpected increase in the number of cases of type 1 diabetes in Sweden, particularly among children under 5 and young adult men. The infection accelerated the onset of diabetes among children between the ages of 5 and 9. The researchers looked at data from a 17-year period on the incidence of type 1 diabetes among all people under the age of 30 in Sweden. In addition, they compared the risk of developing diabetes among 720,000 individuals with positive COVID-19 tests against a control group of 3.5 million people. The findings are published in the journal Diabetologia. The number of diabetes cases increased by 12% in 2021 and 9% in 2022 compared with previous years. In 2023, the number of cases was back to a normal level. Despite this, the researchers cannot distinguish a clear connection between COVID-19 infection and diabetes, except for children between 5 and 9 years old. They had an increased risk of type 1 diabetes about one month after a COVID-19 infection even though their total risk did not increase. "However, it's clear that the COVID-19 vaccine can be ruled out as a cause of the increase in diabetes cases. The recommendation for the age group where we saw the strongest increase was not to get vaccinated. In addition, other studies on adults have shown that vaccination reduces the risk of developing type 1 diabetes after a COVID infection." https://medicalxpress.com/news/2025-10-diabetes-young-people-pandemic.html XX A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious and common complication of the condition, has shown promising results in a University of Bristol study. Findings from this new study, published in Molecular Therapy, demonstrated a 64% reduction in a damage indicator for kidney disease, paving the way for a potential new treatment. The study, explored the potential of delivering a protein called VEGF-C directly into kidney cells. Previous studies have shown VEGFC could protect against kidney disease as it helps keep blood vessels in the kidney filter healthy, repairing early signs of diabetes-related kidney damage. https://medicalxpress.com/news/2025-10-gene-therapy-kidney-disease-diabetes.html XX The FDA has agreed to consider Afrezza inhaled insulin for children and teens. The company said in August that it submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population and it's been assigned a decision deadline date of the end of May, 2026. Afrezza first recieved FDA approval for adults (age 18 and up) in June 2014 https://www.drugdeliverybusiness.com/fda-accepts-application-mannkind-inhaled-insulin-kids/ Update on inhaled insulin for kids.. in the open-label, randomized, phase 3 INHALE-1 clinical trial Afrezza demonstrated safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes (T1D and demonstrates comparable glycemic control to injected rapid-acting insulin. The INHALE-1 clinical trial assessed the safety and efficacy of Afrezza among children and adolescents with T1D, including a total of 230 patients aged 4 to 17 years. Researchers used basal injected insulin and randomly assigned inhaled insulin or rapid-acting analogu

A very common fear among adults with type 1 is having a child diagnosed with T1D. My guest this week was diagnosed at age 7 and he says he held his breath each time one of his three children passed the milestone. But then, his youngest was diagnosed at age 8. I'm talking to Brian Foster about that experience, what surprised him, how everyone's doing now and a lot more. He's also a CDCES and has a master's degree in exercise physiology. Brian is an Ironman triathlete who has completed more than 50 marathons and we get his advice about the endurance sports he loves. Brian's blog My Sweet Hat Trick here Our previous episodes with marathon runners with T1D here Previous episodes with endurance athletes with T1D here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

This week on Diabetes Connections.. Medtronic is making some big moves.. from new sensors, to spinning off the diabetes division. Dr. Jen McVean, medical affairs director at Medtronic's diabetes business. Dr. McVean lives with type 1 and has a real passion for better access and better outcomes using technology. We talk about their latest real-world studies, questions doctors ask about these systems, the new sensors that are now available and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our last episode with Medtronic about their upcoming products and partnerships here (from May 2025) More about Medtronic's new Instinct sensor here More from Medtronic about the news here Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels. Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said. "Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious," Waibel said. "We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence," she added. "If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years." Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas. The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabe

The glucose projector is a simple but powerful idea that can only come from someone who lives with type 1 – and sleeps with it! John DeLeo created a digital readout of CGM data that displays the number, and the time, right on the ceiling. John was diagnosed with type 1 in his 40s. We'll talk about his diagnosis, what lead him to this invention, the long road of bringing it to market, and more. Learn more about Glucose Projector here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

This week on Diabetes Connections.. catching up with Dexcom's Jake Leach.. our first interview with him since Leach was promoted to CEO. As always, a lot going on – we get the details on a recent recall for Dexcom software, studies presented at EASD, a look at what's coming up for the rest of this year and into next and – of course – I ask your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about the FDA letter about direct-to-consumer advertising here Dexcom news from EASD here Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

Managing diabetes data can feel overwhelming, especially when every device speaks a different language. What if your care team could see it all in one place—and have a diabetes educator checking in between visits? This week, we're talking about SweetSpot, a platform that hopes to make everything easier for the doctor and the person with diabetes. This is a big new trend in diabetes care – we're talking about how it works, who pays for it and a lot more with Sweet Spot Director of Diabetes Education and Clinical Services Jodi Hughes, RD, LDN, CDCES This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, "As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before." He added, "If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future." In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it "striking" that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support. https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections. The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs. Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was "probably related" to the use of either immunosuppression or study drugs. In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide). The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems. Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza

Lauren Cox and Gary Forbes both live with type 1 diabetes and both played at the very highest level of the sport: the WNBA and the NBA. Podcaster Rob Howe brought them together as part of the Diabetes Legends Basketball Clinic – an ongoing event for kids and teenagers with type 1 that takes place in different cities around the country. I sat down with all three of them to talk about what it takes to get to that level of pro sports with type 1, what setbacks they had along the way, what keeps them going, and advice they have for families today. This episode was recorded live at the Friends for Life conference This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Diabetes Legends events here Our previous episode with Gary Forbes here Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

This week on Diabetes Connections.. when T1D is one of many chronic conditions. Stacy Abrams was diagnosed with type 1 at age five, and she's faced a slew of other issues since then. Chronic fatigue, celiac, a long road to uncovering mold and environmental illness. She shares the highs and lows of that journey, what helped along the way, and why having a medical team that truly listens makes all the difference. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. "This is the most exciting moment of my scientific career," says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, "opens the future possibility of treating not only diabetes but other autoimmune diseases." This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy's safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it's still too early to consider this approach for a cure, "these options are now here to change the disease in ways that have never been possible before," he says. "There's tremendous hope." https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real. "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds d

We've got an important update on a diabetes drug you may have never heard about. Sotagliflozin is known to have big benefits for people with type 2 but getting it approved for type 1 has been frustrating to say the least. The FDA has twice declined to approve it for people with T1D, but experts – including my guest – are pushing and hoping that will soon change. I'm talking to Dr. Steve Edleman, an endocrinologist who lives with type 1 and heads up the group Take Control of Your Diabetes – TCOYD. We'll talk about the risks that come with sotogliflozin, how continuous ketone monitoring could change the game, and what you can do to push for change. TCOYD's petition here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

We've got a funny, informative, helpful and no holds barred "Ask Me Anything" panels. Recorded at Moms' Night Out in Cleveland, you'll hear from two incredible experts who've lived with type 1 diabetes for decades—Julia Blanchette, PhD, RN, CDCES, and Natalie Bellini, DNP, FNP-BC, CDCES. We tackle everything from helping grandparents understand modern T1D care, to balancing diabetes in a marriage, to managing ADHD alongside diabetes in teens. We'll also dig into why screening for type 1 is so important—and how to find the community and resources that make life with diabetes just a little bit easier. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us for a Back to School webinar - sign up here Join us at an upcoming Moms' Night Out event! Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved. https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning. The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive. Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michae